MX2020013881A - Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. - Google Patents
Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.Info
- Publication number
- MX2020013881A MX2020013881A MX2020013881A MX2020013881A MX2020013881A MX 2020013881 A MX2020013881 A MX 2020013881A MX 2020013881 A MX2020013881 A MX 2020013881A MX 2020013881 A MX2020013881 A MX 2020013881A MX 2020013881 A MX2020013881 A MX 2020013881A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- drug conjugates
- antibody drug
- same
- inhibitory compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
En la presente se dan a conocer inhibidores de Bcl-xL de molécula pequeña y conjugados de anticuerpo-fármaco (ADC) que comprenden los inhibidores de Bcl-xL de molécula pequeña. Los inhibidores de Bcl-xL y los ADC de la invención son útiles, entre otras cosas, para inhibir las proteínas Bcl-xL anti-apoptóticas como un planteamiento terapéutico para el tratamiento de enfermedades que involucran una senda de apoptosis mal regulada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462089794P | 2014-12-09 | 2014-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020013881A true MX2020013881A (es) | 2021-03-09 |
Family
ID=55135514
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007637A MX2017007637A (es) | 2014-12-09 | 2015-12-09 | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
MX2020013881A MX2020013881A (es) | 2014-12-09 | 2017-06-09 | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007637A MX2017007637A (es) | 2014-12-09 | 2015-12-09 | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. |
Country Status (9)
Country | Link |
---|---|
US (2) | US20160158377A1 (es) |
EP (1) | EP3230283A1 (es) |
JP (2) | JP2018502839A (es) |
CN (2) | CN107207553A (es) |
AU (2) | AU2015360621A1 (es) |
BR (1) | BR112017012342A2 (es) |
CA (1) | CA2970161A1 (es) |
MX (2) | MX2017007637A (es) |
WO (1) | WO2016094517A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
CN113209306A (zh) * | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
RU2017123942A (ru) * | 2014-12-09 | 2019-01-11 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их |
WO2017051249A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-cd19 antibody drug conjugates |
WO2017051254A1 (en) | 2015-09-25 | 2017-03-30 | Legochem Biosciences, Inc. | Compositions and methods related to anti-egfr antibody drug conjugates |
CA3006247A1 (en) | 2015-11-25 | 2017-06-01 | Legochem Biosciences, Inc. | Conjugates comprising peptide groups and methods related thereto |
EP3380126A4 (en) | 2015-11-25 | 2019-07-24 | LegoChem Biosciences, Inc. | ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS |
US11413353B2 (en) | 2015-11-25 | 2022-08-16 | Legochem Biosciences, Inc. | Conjugates comprising self-immolative groups and methods related thereto |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
CN109311948B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 清洁和/或消毒分离基质的方法 |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
ES2874974T3 (es) | 2016-05-11 | 2021-11-05 | Cytiva Bioprocess R & D Ab | Matriz de separación |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
EP3835322A3 (en) | 2016-06-08 | 2021-10-06 | AbbVie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
AU2017277534A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
EP3468615A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
MX2018015285A (es) | 2016-06-08 | 2019-09-18 | Abbvie Inc | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. |
JP2019521106A (ja) * | 2016-06-08 | 2019-07-25 | アッヴィ・インコーポレイテッド | 抗egfr抗体薬物コンジュゲート |
IL266353B2 (en) | 2016-11-08 | 2024-03-01 | Regeneron Pharma | Steroids and their protein conjugates |
CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
US11491237B2 (en) | 2017-05-18 | 2022-11-08 | Regeneron Pharmaceuticals, Inc. | Cyclodextrin protein drug conjugates |
EP3424539A1 (en) * | 2017-07-06 | 2019-01-09 | The Procter & Gamble Company | Malodor reduction compositions |
KR20200085807A (ko) * | 2017-11-07 | 2020-07-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항체 약물 접합제용 친수성 링커 |
MX2020011554A (es) | 2018-05-09 | 2020-11-24 | Legochem Biosciences Inc | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19). |
CA3098453A1 (en) | 2018-05-09 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
CN108341769A (zh) * | 2018-05-13 | 2018-07-31 | 浙江凯普化工有限公司 | 多取代的6-氟皮考啉酸的制备方法 |
TW202015740A (zh) * | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
CN112262152A (zh) * | 2018-06-14 | 2021-01-22 | 味之素株式会社 | 具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐 |
WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
KR20210028544A (ko) | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
WO2022115477A1 (en) | 2020-11-24 | 2022-06-02 | Novartis Ag | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
IL304891A (en) | 2021-02-02 | 2023-10-01 | Servier Lab | Selective Protech BCL-XL compounds and methods of use |
CN115340502B (zh) * | 2021-05-13 | 2024-02-23 | 成都先导药物开发股份有限公司 | Bcl-xl抑制剂及其制备方法和用途 |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
CN114874287B (zh) * | 2022-05-20 | 2024-04-02 | 联宁(苏州)生物制药有限公司 | 一种抗体偶联药物-连接子lnd1042的合成方法 |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023236814A1 (zh) * | 2022-06-10 | 2023-12-14 | 成都先导药物开发股份有限公司 | 一种化合物及其在制备bcl-xl抑制剂中的用途 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
AU2003256038A1 (en) | 2002-08-30 | 2004-03-19 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
AU2003282624A1 (en) | 2002-11-14 | 2004-06-03 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
BR122018071968B8 (pt) * | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
RU2489423C2 (ru) | 2006-02-02 | 2013-08-10 | Синтарга Б.В. | Водорастворимые аналоги сс-1065 и их конъюгаты |
TW200900059A (en) * | 2007-02-21 | 2009-01-01 | Medarex Inc | Chemical linkers with single amino acids and conjugates thereof |
EP2144628B1 (en) * | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
EP2373163B1 (en) * | 2008-12-19 | 2015-06-10 | Genentech, Inc. | Heterocyclic compounds and methods of use |
CA2747161C (en) * | 2008-12-19 | 2017-07-18 | Abbott Laboratories | (hetero)aryl substituted (benzo[d]thiazol-2-ylcarbamoyl) 1,2,3,4-tetrahydroquinolins and related compounds and uses thereof for treating cancer and excess platelets |
CN103958508B (zh) * | 2011-10-14 | 2019-02-12 | 艾伯维公司 | 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂 |
TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
US8889675B2 (en) * | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
AU2012348017A1 (en) | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
US20130280282A1 (en) * | 2012-04-24 | 2013-10-24 | Daiichi Sankyo Co., Ltd. | Dr5 ligand drug conjugates |
BR112014028222A2 (pt) * | 2012-05-15 | 2017-06-27 | Seattle Genetics Inc | conjugados vinculadores auto-estabilizantes. |
US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
CN113209306A (zh) * | 2014-12-09 | 2021-08-06 | 艾伯维公司 | 具有细胞渗透性的bcl-xl抑制剂的抗体药物缀合物 |
RU2017123942A (ru) * | 2014-12-09 | 2019-01-11 | Эббви Инк. | Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их |
-
2015
- 2015-12-09 US US14/963,510 patent/US20160158377A1/en not_active Abandoned
- 2015-12-09 CA CA2970161A patent/CA2970161A1/en not_active Abandoned
- 2015-12-09 WO PCT/US2015/064706 patent/WO2016094517A1/en active Application Filing
- 2015-12-09 EP EP15823857.6A patent/EP3230283A1/en not_active Withdrawn
- 2015-12-09 AU AU2015360621A patent/AU2015360621A1/en not_active Abandoned
- 2015-12-09 BR BR112017012342A patent/BR112017012342A2/pt not_active Application Discontinuation
- 2015-12-09 CN CN201580075763.5A patent/CN107207553A/zh active Pending
- 2015-12-09 JP JP2017530624A patent/JP2018502839A/ja active Pending
- 2015-12-09 MX MX2017007637A patent/MX2017007637A/es unknown
- 2015-12-09 CN CN202010429701.2A patent/CN111620862A/zh active Pending
-
2017
- 2017-06-09 MX MX2020013881A patent/MX2020013881A/es unknown
-
2019
- 2019-11-06 US US16/675,784 patent/US20200239553A1/en not_active Abandoned
-
2020
- 2020-04-14 JP JP2020072142A patent/JP2020128378A/ja active Pending
- 2020-07-29 AU AU2020210220A patent/AU2020210220A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200239553A1 (en) | 2020-07-30 |
JP2020128378A (ja) | 2020-08-27 |
WO2016094517A1 (en) | 2016-06-16 |
AU2020210220A1 (en) | 2020-08-20 |
EP3230283A1 (en) | 2017-10-18 |
US20160158377A1 (en) | 2016-06-09 |
MX2017007637A (es) | 2017-09-05 |
BR112017012342A2 (pt) | 2018-02-27 |
AU2015360621A1 (en) | 2017-06-29 |
CN107207553A (zh) | 2017-09-26 |
JP2018502839A (ja) | 2018-02-01 |
CN111620862A (zh) | 2020-09-04 |
CA2970161A1 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020013881A (es) | Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen. | |
MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
TW201613901A (en) | New compounds | |
CA2956871C (en) | Compounds active towards bromodomains | |
WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
MX2017007629A (es) | Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen. | |
IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
SG10201806849WA (en) | Cyclopropylamines as lsd1 inhibitors | |
EP3256218A4 (en) | Kdm1a inhibitors for the treatment of disease | |
MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
PH12016501830A1 (en) | Inhibitors of c5a for the treatment of viral pneumonia | |
MX2023002507A (es) | Inhibidores de cd73. | |
EP3436002A4 (en) | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER | |
EP3148532A4 (en) | Pharmaceutical combination for the treatment of cancer | |
EP3572095A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HTLV-1 ASSOCIATED MYELOPATHIA | |
EP3156055A4 (en) | Pharmaceutical composition for preventing or treating muscular weakness-related diseases, containing butylpyridinium or derivative thereof | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EP3275450A4 (en) | Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
EP3371176A4 (en) | EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND MEDICAMENT CONJUGATES THEREOF | |
EA201700254A1 (ru) | Комбинация | |
EP3190129A4 (en) | Centrally-acting peptide derivative, and pharmaceutical composition | |
EP3471775A4 (en) | HEMOGLOBIN-TARGETED DRUG ADMINISTRATION FOR CANCER TREATMENT |